FLT3 and leukemia: HHT combined with a Bcl-2 inhibitor antagonizes the FLT3-STAT5 pathway by downregulating the expression of Bcl-2 and Mcl-1 (203) and also interferes with the PI3K/AKT/GSK3β pathway to effectively treat leukemia (204).